Details of Disease

General Information of Disease (ID: DIS7U38D)

Disease Name	Varicella zoster virus infection
Synonyms	varicella zoster infection; Varicella-zoster Virus infection
Disease Class	1E91: Zoster
Definition	A highly contagious viral infection caused by the varicella zoster virus. Clinically, it may be manifested as shingles or chicken pox.
Disease Hierarchy	DISDI77C: Primary viral infectious disease DISEM33Q: Infectious disease DIS7U38D: Varicella zoster virus infection
ICD Code	ICD-11 ICD-11: 1E91
Disease Identifiers	MONDO ID MONDO_0005608 MESH ID D000073618 UMLS CUI C0586989 MedGen ID 668886 SNOMED CT ID 309465005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 5 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Priorix	DMW1EOF	Approved	NA	[1]
ProQuad	DMC26Y5	Approved	NA	[1]
Varicella-zoster immune globulin	DM8KWTT	Approved	NA	[1]
Varilrix	DMGM8R0	Approved	NA	[1]
Zostavax	DMYPG87	Approved	NA	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
FV-100	DMZARP1	Phase 3	Small molecular drug	[2]
V-212	DMS2V7Y	Phase 3	NA	[3]
Albuterpenoids	DMMU532	Phase 2	NA	[4]
Valomaciclovir stearate	DMAEB9O	Phase 2	Small molecular drug	[5]
CRV-101	DM2526O	Phase 1	Vaccine	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 1 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
IDE	TT2EDHU	Strong	Biomarker	[7]
------------------------------------------------------------------------------------

This Disease Is Related to 1 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
FAM3B	OTC2S91N	Strong	Biomarker	[8]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	ClinicalTrials.gov (NCT02412917) A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia. U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT01254630) A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011). U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT02024581) A Dose Range-Finding Phase 2 Trial of a Botanical Drug for the Treatment of Molluscum Contagiosum in Pediatric Subjects. U.S. National Institutes of Health.
5	ClinicalTrials.gov (NCT00831103) A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster. U.S. National Institutes of Health.
6	ClinicalTrials.gov (NCT03820414) Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects. U.S. National Institutes of Health.
7	Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread.Cell. 2006 Oct 20;127(2):305-16. doi: 10.1016/j.cell.2006.08.046.
8	ORF11 protein interacts with the ORF9 essential tegument protein in varicella-zoster virus infection.J Virol. 2013 May;87(9):5106-17. doi: 10.1128/JVI.00102-13. Epub 2013 Feb 20.